This analysis could provide useful information for identifying those ruxolitinib-treated patients that are at higher risk of SARS- CoV-2 infection and assessing prognostic factors for survival in a homogeneously treated cohort. The final objective is to provide decision-support tools for viral therapy and/or hospitalization.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
Massimiliano Bonifacio;Eleonora Santoni;Mauro Krampera;
2023-01-01
Abstract
This analysis could provide useful information for identifying those ruxolitinib-treated patients that are at higher risk of SARS- CoV-2 infection and assessing prognostic factors for survival in a homogeneously treated cohort. The final objective is to provide decision-support tools for viral therapy and/or hospitalization.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
